Back to Search
Start Over
Response to: ‘The cost of arthralgia ‘pretreatment’ to prevent rheumatoid arthritis’ by Rothschild
- Source :
- Annals of the Rheumatic Diseases, 81(2). BMJ Publishing Group, Annals of the rheumatic diseases, 81(2). BMJ Publishing Group
- Publication Year :
- 2020
- Publisher :
- BMJ, 2020.
-
Abstract
- We read the letter from Rothschild with interest.1 We agree that we need more data and better evidence on: (1) how to determine the risk of patients with arthralgia progressing to ‘true RA’ and on (2) whether or not Disease Modifying AntiRheumatic Drug (DMARD) treatment is better than placebo in this phase. Both points were discussed in our Viewpoint.2 Cost–benefit analyses can only be performed afterwards. Rothschild seems to …
- Subjects :
- rheumatoid arthritis
0301 basic medicine
medicine.medical_specialty
medicine.medical_treatment
Immunology
MEDLINE
Placebo
General Biochemistry, Genetics and Molecular Biology
Arthritis, Rheumatoid
03 medical and health sciences
0302 clinical medicine
Rheumatology
Internal medicine
medicine
Humans
Immunology and Allergy
Rothschild
Disease-modifying antirheumatic drug
030203 arthritis & rheumatology
treatment
business.industry
medicine.disease
Arthralgia
030104 developmental biology
Antirheumatic Agents
Rheumatoid arthritis
DMARDs (synthetic)
business
Subjects
Details
- ISSN :
- 14682060 and 00034967
- Volume :
- 81
- Database :
- OpenAIRE
- Journal :
- Annals of the Rheumatic Diseases
- Accession number :
- edsair.doi.dedup.....3aacf6c0e643d6b4d6cfb7065d478869
- Full Text :
- https://doi.org/10.1136/annrheumdis-2020-216984